Pain

Radicle Science and Open Book Extracts release results of the largest ever blinded, randomized clinical trial on cannabinoids and pain—and the first study of its kind to examine the impact of rare cannabinoids.

Mechanistic insights into cannabinoid signaling could improve therapeutic applications.

Cannabidiol (CBD) is a highly touted product for many different disorders among the lay press. Numerous CBD products are available, ranging from a US Food and Drug Administration (FDA)-approved product called Epidiolex to products created for medical marijuana dispensaries and products sold in smoke shops, convenience stores, and over the Internet.

CBD’s potential to reduce cue-induced craving and anxiety provides a strong basis for further investigation of this phytocannabinoid as a treatment option for opioid use disorder.

Cannabinoids have a long record of recreational and medical use and become increasingly approved for pain therapy. This development is based on preclinical and human experimental research summarized in this review.